Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service structural heart (TAVR, TEER) cases in Colorado: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 34 | 641 | 46% |
| 2020 | 35 | 569 | 48% |
| 2021 | 38 | 685 | 50% |
| 2022 | 36 | 795 | 53% |
| 2023 | 39 | 792 | 55% |
| 2024 | 33 | 787 | 57% |
| 2025 from claims | – | 860 695–1,010 | 57% |
| 2026 forecast | – | 923 723–1,160 | 56% |
| 2027 forecast | – | 972 721–1,285 | 56% |
| 2028 forecast | – | 1,023 724–1,412 | 57% |
| 2029 forecast | – | 1,077 732–1,544 | 57% |
| 2030 forecast | – | 1,134 743–1,682 | 57% |
Transcatheter aortic valve replacement and mitral edge-to-edge repair. Professional codes (what the surgeon bills): CPT 33361, 33362, 33363, 33364, 33365, 33366, 33418, 33419; the hospital bills MS-DRG 266, 267.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 56% of the cases CMS names in Colorado; 20 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 99% inpatient hospital, 1% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 238 | 5,995+3.6%/yr | +3.6%/yr | 1.5 | 0% | 8,310 in 2030+5.6%/yr |
| Washington | 65 | 1,756+5.4%/yr | +5.4%/yr | 1.9 | 0% | 2,430 in 2030+5.5%/yr |
| Arizona | 74 | 1,643+5.5%/yr | +5.5%/yr | 1.9 | 0% | 2,270 in 2030+5.5%/yr |
| Oregon | 39 | 802+2.6%/yr | +2.6%/yr | 1.6 | 0% | 1,140 in 2030+6%/yr |
| Nevada | 30 | 487+4.8%/yr | +4.8%/yr | 1.4 | 0% | 610 in 2030+3.7%/yr |
| Utah | 21 | 422−1.7%/yr | −1.7%/yr | 1.6 | 0% | 410 in 2030−0.3%/yr |
| Montana | 15 | 357+1.6%/yr | +1.6%/yr | 1.7 | 0% | 480 in 2030+5.2%/yr |
| Idaho | 17 | 257+2.2%/yr | +2.2%/yr | 1.1 | 0% | 530 in 2030+13%/yr |
| New Mexico | 9 | 207+20%/yr | +20%/yr | 0.8 | 0% | 260 in 2030+4%/yr |
| Alaska | 5 | 100+16%/yr | +16%/yr | 0.8 | 0% | 190 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 63 | 2,688−3.7%/yr | −3.7%/yr | 4.51.0× | 1% | 3,050 in 2030+2.1%/yr |
| Mechanical circulatory support | 0 | 158−8.8%/yr | −8.8%/yr | 0.30.7× | 0% | 190 in 2030+3.2%/yr |
Structural heart (TAVR, TEER) in every state, and its device makers · Every procedure market in Colorado · Every state · Compare with California
Edwards Lifesciences leads with 46% of company spending on these surgeons in 2025, −10 pts on 2024.
In 2025, 6 companies reported engagement with Colorado’s surgeons worth $508K in consulting, speaking, meals and travel tied to these products, about $15K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 52 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.